pyrazines has been researched along with carnitine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dou, QP; Guan, L; Guo, H; Huang, H; Li, B; Li, X; Liao, S; Liu, C; Liu, J; Liu, N; Liu, S; Song, W; Tang, P; Xu, L; Yang, C; Zhang, C; Zhao, K | 1 |
| Gong, X; He, X; Sun, M; Sun, Y; Wang, BO; Wang, M; Wang, X; Wang, Z; Wei, X; Yi, F; Zhang, Y; Zhou, Z | 1 |
2 other study(ies) available for pyrazines and carnitine
| Article | Year |
|---|---|
HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
Topics: Acetylation; Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Carnitine; Caspases; Cell Death; Cell Proliferation; Chromatin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Endoplasmic Reticulum Stress; Enzyme Activation; Hep G2 Cells; Histone Deacetylase Inhibitors; Histones; Humans; Male; Mice; Models, Biological; Poly(ADP-ribose) Polymerases; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2012 |
Therapeutic Potential of Novel Twin Compounds Containing Tetramethylpyrazine and Carnitine Substructures in Experimental Ischemic Stroke.
Topics: Animals; Brain Ischemia; Carnitine; Disease Models, Animal; Male; NADPH Oxidase 2; Neuroprotective Agents; Pyrazines; Rats; Rats, Sprague-Dawley; Stroke | 2017 |